Carregando...
Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world
BACKGROUND: To identify factors for starting biosimilar TNF inhibitors (TNFI) in patients with rheumatic diseases. METHODS AND FINDING: Using a national claims database, we identified patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) who had used TNFIs since they were approved i...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Principais autores: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6980538/ https://ncbi.nlm.nih.gov/pubmed/31978121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0227960 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|